2025 – PHAXIAM Therapeutics announces judicial liquidation and delisting.
PHAXIAM Therapeutics is a clinical-stage biopharmaceutical company pioneering precision phage therapy and lysins to combat antibiotic-resistant bacterial infections. Formed in 2023 through the merger of Pherecydes Pharma (a phage therapy specialist founded in 2006) and ERYTECH Pharma’s clinical-stage assets, PHAXIAM uniquely combines:
- Natural phage expertise: Clinically validated, pathogen-specific bacteriophage cocktails.
- Synthetic biology: Engineered lysins (E-Xplore® platform) for enhanced bactericidal activity.
- Diagnostic integration: Partnering with diagnostics firms to enable personalized treatment.
The company focuses on high-mortality infections with limited treatment options, including prosthetic joint infections (PJI), diabetic foot osteomyelitis (DFO), and respiratory infections in cystic fibrosis patients.
PHAXIAM Therapeutics technology includes:
- PhageBank® Platform: One of the world’s largest proprietary phage libraries (>1,000 characterized phages) with the ability to create customized cocktails tailored to individual patient pathogens (48h turnaround).
Bacteriophage product pipeline:
- Target: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli for prosthetic joint infections (PJI) and diabetic foot osteomyelitis (DFO).
Lysin product pipeline:
- E-Xplore®: Engineered lysin targeting Gram-positive pathogens.
